VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

rVSV- SEBOV-GP and -VP40
Vaccine Information
  • Vaccine Name: rVSV- SEBOV-GP and -VP40
  • Target Pathogen: Ebola virus
  • Target Disease: Ebola hemorrhagic fever
  • Vaccine Ontology ID: VO_0004661
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • NP from Zaire Ebola virus gene engineering:
    • Type: Recombinant vector construction
    • Description: New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP (Marzi et al., 2011).
    • Detailed Gene Information: Click Here.
  • VP40 from Zaire ebolavirus gene engineering:
    • Type: Recombinant vector construction
    • Description: New vectors were generated that contain EBOV viral protein 40 (VP40) or EBOV nucleoprotein (NP) as a second antigen expressed by the same rVSV vector that encodes the heterologous GP (Marzi et al., 2011).
    • Detailed Gene Information: Click Here.
  • Vector:
  • Preparation: rVSV-expressing SEBOV-GP and -VP40 (Marzi et al., 2011; Falzarano et al., 2011).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Guinea pig Response

  • Vaccination Protocol: The guinea pigs were vaccinated intraperitoneally with a single dose of 2 ×10^5 PFU to guinea pigs of rVSV (Marzi et al., 2011).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: The guinea pigs were subsequently challenged with 1000 LD50 of GPA-ZEBOV [20] or boosted with the same dose of rVSV and challenged 3 weeks later (Marzi et al., 2011).
  • Efficacy: After applying a 2-dose immunization approach, we observed an improved cross-protection rate, with 5 of 6 guinea pigs surviving the lethal ZEBOV challenge if vaccinated with rVSV-expressing SEBOV-GP and -VP40 (Marzi et al., 2011).
References
Falzarano et al., 2011: Falzarano D, Feldmann F, Grolla A, Leung A, Ebihara H, Strong JE, Marzi A, Takada A, Jones S, Gren J, Geisbert J, Jones SM, Geisbert TW, Feldmann H. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus. The Journal of infectious diseases. 2011; 204 Suppl 3; S1082-1089. [PubMed: 21987745].
Marzi et al., 2011: Marzi A, Ebihara H, Callison J, Groseth A, Williams KJ, Geisbert TW, Feldmann H. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. The Journal of infectious diseases. 2011; 204 Suppl 3; S1066-1074. [PubMed: 21987743].